Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Ascletis Pharma has reported positive topline outcomes from its US Phase Ia SAD study of the oral tablet, ASC30, in obese ...

A gut microbe could naturally regulate sugar cravings and blood sugar levels, offering a promising alternative to drugs like ...

The soaring demand for antidiabetic and weight-loss drugs has lured in many biotech and big Pharma companies. Onto this ...

epinephrine and glucagon rapidly increase the amount of active phosphorylase in pre-incubated liver slices 1,2. In order to study the nature of the change in the phosphorylase molecule ...

Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.

The San Diego–based company’s molecules avoid the well-trod GLP-1 pathway in favor of an alternate route in the gut.

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...